<DOC>
	<DOCNO>NCT00519324</DOCNO>
	<brief_summary>The purpose study assess efficacy safety everolimus 10mg daily patient advance gastric carcinoma ( inoperable , recurrent metastatic gastric cancer ) whose cancer progress despite prior treatment .</brief_summary>
	<brief_title>Efficacy Safety Everolimus ( RAD001 ) Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Histological proven gastric adenocarcinoma Progressive disease during/ prior treatment Treated 1 2 chemotherapy regimen advance disease At least one measurable lesion RECIST criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Exclusion criterion : History another primary malignancy within 3 year Treated 3 regimen advanced gastric cancer Chronic treatment steroid another immunosuppressive agent A known history HIV hepatitis B seropositive , active hepatitis C infection Patients active , bleeding diathesis Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>RAD001</keyword>
	<keyword>mTOR</keyword>
</DOC>